Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2416 to 2430 of 7684 results

  1. Violence and Aggression: short-term management in mental health, health and community settings

    In development [GID-NG10432] Expected publication date: TBC

  2. Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]

    In development [GID-TA11485] Expected publication date: 20 August 2025

  3. Teprotumumab for treating thyroid eye disease [ID6432]

    In development [GID-TA11531] Expected publication date: 20 August 2025

  4. Mepolizumab for reducing eosinophilic exacerbations of chronic obstructive pulmonary disease [ID1237]

    Awaiting development [GID-TA10239] Expected publication date: TBC

  5. Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256

    In development [GID-TA11279] Expected publication date: 20 August 2025

  6. Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]

    In development [GID-TA11232] Expected publication date: 20 August 2025

  7. Robot-assisted surgery for soft-tissue procedures: early value assessment

    In development [GID-HTE10040] Expected publication date: 31 March 2025

  8. Leadless cardiac pacemaker implantation for bradyarrhythmias

    Awaiting development [GID-IPG10340] Expected publication date: 13 November 2025

  9. Low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer

    Awaiting development [GID-IPG10412] Expected publication date: 13 November 2025

  10. Venoarterial extracorporeal membrane oxygenation (VA ECMO) for acute heart failure in adults

    In development [GID-IPG10411] Expected publication date: 06 August 2025

  11. Balloon cryoablation for Barrett's oesophagus

    Awaiting development [GID-IPG10413] Expected publication date: TBC

  12. Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]

    In development [GID-TA11439] Expected publication date: TBC

  13. Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a cancer drug in people 12 years and over (managed access review of TA742) [ID6288]

    In development [GID-TA11398] Expected publication date: TBC

  14. Tolebrutinib for treating relapsing multiple sclerosis ID6351

    Awaiting development [GID-TA11333] Expected publication date: TBC

  15. Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy ID6409

    In development [GID-TA11508] Expected publication date: TBC